Collimator High-Energy for Collimator Evaluating 223 Is Preferable Ra Uptake to in Medium-Energy Bone Metastasis at 2 Weeks Postinjection

Akira Ichimura, Tadaki Nakahara, Yoshiki Owaki, Kiyotaka Nakajima, Masahiro Jinzaki

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

An 80-year-old man with castration-resistant prostate cancer received 223Ra injection to treat bone metastases. Two weeks after the injection, the patient underwent static 223Ra scan of the chest with medium-energy and high-energy collimators for 30 minutes each. Images obtained with the 2 collimators showed that uptake in metastatic lesions was visually clearer and semiquantitatively higher with the high-energy collimator. The use of HE collimator for 223Ra imaging in the early phase has been reported, and the present case suggests that in the late phase HE collimator would also be preferable to medium-energy collimator in terms of lesion-based evaluation.

Original languageEnglish
Pages (from-to)71-72
Number of pages2
JournalClinical nuclear medicine
Volume43
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Keywords

  • Bone metastasis
  • High-energy collimator
  • Ra

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Collimator High-Energy for Collimator Evaluating 223 Is Preferable Ra Uptake to in Medium-Energy Bone Metastasis at 2 Weeks Postinjection'. Together they form a unique fingerprint.

Cite this